NO20044053L - Farnesylproteintransferaseinhibitorer som antitumormidler - Google Patents

Farnesylproteintransferaseinhibitorer som antitumormidler

Info

Publication number
NO20044053L
NO20044053L NO20044053A NO20044053A NO20044053L NO 20044053 L NO20044053 L NO 20044053L NO 20044053 A NO20044053 A NO 20044053A NO 20044053 A NO20044053 A NO 20044053A NO 20044053 L NO20044053 L NO 20044053L
Authority
NO
Norway
Prior art keywords
protein transferase
antitumor agents
transferase inhibitors
farnesyl protein
farnesyl
Prior art date
Application number
NO20044053A
Other languages
English (en)
Inventor
Alan Bruce Cooper
John J Baldwin
Viyyoor Moopil Girijavallabhan
Carmen S Alvarez
Walter Robert Bishop
Timothy J Guzi
James J S Wang
Bancha Vibulbhan
F George Njoroge
Patrick A Pinto
Bama Santhanam
Keith P Minor
Ronald J Doll
Hugh Y Zhu
Kartik M Keertikar
Jagdish A Desai
Ge Li
Chia-Yu Huang
Ray Anthony James
Dinanath F Rane
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20044053L publication Critical patent/NO20044053L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20044053A 2002-02-27 2004-09-24 Farnesylproteintransferaseinhibitorer som antitumormidler NO20044053L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
NO20044053L true NO20044053L (no) 2004-11-26

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044053A NO20044053L (no) 2002-02-27 2004-09-24 Farnesylproteintransferaseinhibitorer som antitumormidler

Country Status (19)

Country Link
US (1) US7342016B2 (no)
EP (1) EP1492772A1 (no)
JP (1) JP2005525356A (no)
KR (1) KR20040098004A (no)
CN (1) CN100537542C (no)
AR (1) AR039557A1 (no)
AU (1) AU2003215389B2 (no)
BR (1) BR0308071A (no)
CA (1) CA2477328A1 (no)
CO (1) CO5611194A2 (no)
IL (1) IL163673A0 (no)
MX (1) MXPA04008303A (no)
NO (1) NO20044053L (no)
NZ (1) NZ534809A (no)
PE (1) PE20031038A1 (no)
PL (1) PL372335A1 (no)
RU (1) RU2004128465A (no)
TW (1) TW200303867A (no)
WO (1) WO2003072549A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
TWI577695B (zh) * 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子(vegf)-特異性拮抗劑及早期腫瘤之治療
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
IL133389A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
CA2294347C (en) 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
PE86199A1 (es) 1997-06-17 1999-09-24 Schering Corp Sulfonamida inhibidor de la enzima farnesilo transferasa
HUP0003138A3 (en) 1997-06-17 2002-11-28 Schering Corp Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
PL348293A1 (en) 1998-12-18 2002-05-20 Schering Corp Tricyclic farnesyl protein transferase inhibitors
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.

Also Published As

Publication number Publication date
RU2004128465A (ru) 2005-09-27
AU2003215389A1 (en) 2003-09-09
JP2005525356A (ja) 2005-08-25
AR039557A1 (es) 2005-02-23
US20040122018A1 (en) 2004-06-24
KR20040098004A (ko) 2004-11-18
CA2477328A1 (en) 2003-09-04
PE20031038A1 (es) 2004-01-10
NZ534809A (en) 2007-12-21
CN100537542C (zh) 2009-09-09
WO2003072549A1 (en) 2003-09-04
AU2003215389B2 (en) 2007-10-18
CO5611194A2 (es) 2006-02-28
PL372335A1 (en) 2005-07-11
US7342016B2 (en) 2008-03-11
TW200303867A (en) 2003-09-16
CN1630641A (zh) 2005-06-22
EP1492772A1 (en) 2005-01-05
MXPA04008303A (es) 2005-11-23
BR0308071A (pt) 2004-12-21
IL163673A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20050426L (no) Arylkarbonylderivater som terapeutiske midler
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20043886L (no) Et follistatindomene som inneholder proteiner
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NO20044053L (no) Farnesylproteintransferaseinhibitorer som antitumormidler
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20035728L (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1438289T3 (da) Indolderivater som cox II-inhibitorer
NO20030918L (no) Trisykliske antitumorforbindelser som er farnesylproteintransferaseinhibitorer
IL173514A0 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
DE60329174D1 (de) Mehrwegventil
DK1499622T3 (da) Meterotricyclyl-6-alkylidenpenemer som beta-lactamaseinhibitorer
ZA200705126B (en) Novel farnesyl protein transferase inhibitors as antitumor agents